Form 4: Baker Bros. Advisors Reports Denali Equity Grant

Director Julian C. Baker received a grant of restricted stock units and stock options from Denali Therapeutics Inc. as part of his board compensation.

Summary

• Julian C. Baker, a director of Denali Therapeutics Inc., was granted 6,408 restricted stock units (RSUs) and 19,226 non-qualified stock options on June 3, 2026.
• The stock options have an exercise price of $19.66 and an expiration date of June 3, 2036.
• The RSUs and options vest on the earlier of June 3, 2027, or the day prior to the company's next annual meeting.
• The reporting persons, including Baker Bros. Advisors LP and associated funds, disclaim direct pecuniary interest in these securities, noting they are held for the benefit of the funds.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding standard director compensation, carrying no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new equity grants to board members.

Risks

• Vesting is contingent upon continuous service on the board of directors.
• Market price volatility could impact the future value of the granted options and RSUs.

Future Outlook

The securities are subject to a one-year vesting period, aligning the director's tenure with the company's performance through mid-2027.

Management Comments

• The grants were issued pursuant to the Issuer's 2017 Equity Incentive Plan and Outside Director Compensation Policy.

Industry Context

StockSavvy.ai notes that equity grants to board members of biotech firms are standard practice to ensure alignment between institutional investors and company leadership, particularly when those directors represent significant investment funds.

Comparison to Industry Standards

• The use of RSUs and stock options for board compensation is consistent with standard corporate governance practices for NASDAQ-listed biotechnology companies.
• The vesting schedule of one year is typical for annual director equity refresh grants.

Corporate Governance

Related Party Transactions

• The reporting persons are affiliated with major shareholders (667, L.P. and Baker Brothers Life Sciences, L.P.) and have disclosed their indirect pecuniary interests in the granted securities.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity to directors.

Next Steps

• Vesting of RSUs and options on June 3, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Denali Therapeutics, DNLI, Baker Bros. Advisors, Insider Trading, Form 4, Equity Compensation, Biotech